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Abstract
 
The triggering receptor expressed on myeloid cells (TREM)-1 is a recently discovered receptor
expressed on the surface of neutrophils and a subset of monocytes. Engagement of TREM-1 has
been reported to trigger the synthesis of proinflammatory cytokines in the presence of microbial
products. Previously, we have identified a soluble form of TREM-1 (sTREM-1) and observed
significant levels in serum samples from septic shock patients but not controls. Here, we investi-
gated its putative role in the modulation of inflammation during sepsis. We observed that
sTREM-1 was secreted by monocytes activated in vitro by LPS and in the serum of animals in-
volved in an experimental model of septic shock. Both in vitro and in vivo, a synthetic peptide
mimicking a short highly conserved domain of sTREM-1 appeared to attenuate cytokine pro-
duction by human monocytes and protect septic animals from hyper-responsiveness and death.
This peptide seemed to be efficient not only in preventing but also in down-modulating the del-
eterious effects of proinflammatory cytokines. These data suggest that in vivo modulation of
TREM-1 by sTREM peptide might be a suitable therapeutic tool for the treatment of sepsis.
Key words: triggering receptor expressed on myeloid cells-1 • inﬂammation • sepsis • 
proinﬂammatory cytokines • mouse model
 
Introduction
 
After an infection, innate and cognitive immune responses
develop in sequential phases that build up in specificity and
complexity, resulting ultimately in the clearance of infec-
tious agents and restoration of homeostasis. The innate im-
mune response serves as the first line of defense and is initi-
ated upon activation of pattern recognition receptors, such
as Toll-like receptors (TLRs) (1, 2), by various pathogen-
associated microbial patterns (3). Activation of the TLRs
triggers the release of large quantities of such cytokines as
TNF-
 
 
 
 and IL-1
 
 
 
, which, in case of such massive infec-
tions as sepsis, can precipitate tissue injury and lethal shock
(4, 5). Although antagonists of TNF-
 
 
 
 and IL-1
 
 
 
 appeared
in this context as possibly interesting therapeutic agents of
sepsis, they have unfortunately shown limited efficacy in
clinical trials (6–8). This could be due to the fact that these
cytokines are necessary for the clearance of infections and
that their removal would allow for fatal bacterial growth
(9–11).
The triggering receptor expressed on myeloid cells
(TREM)-1 is a recently discovered cell-surface molecule
that has been identified both on human and murine poly-
morphonuclear neutrophils and mature monocytes (12). It
belongs to the immunoglobulin superfamily and activates
downstream signaling pathways with the help of an adaptor
protein called DAP12 (12–15). Bouchon and coworkers
have shown that the expression of TREM-1 was greatly
up-regulated on neutrophils and monocytes in the presence
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of such bacteria as 
 
Pseudomonas aeruginosa
 
 or 
 
Staphylococcus
aureus
 
, both in cell culture and in tissue samples from pa-
tients with infection (16). In striking contrast, TREM-1
was not up-regulated in samples from patients with nonin-
fectious inflammatory diseases such as psoriasis, ulcerative
colitis, or vasculitis caused by immune complexes (16).
Moreover, when TREM-1 is bound to its ligand there is a
synergistic effect of LPS and an amplified synthesis of the
proinflammatory cytokines TNF-
 
 
 
 and GM-CSF, together
with an inhibition of IL-10 production (17). In a murine
model of LPS-induced septic shock, blockade of TREM-1
signaling protected the animals from death, further high-
lighting the crucial role of this molecule (13, 16).
Here we show that a soluble form of TREM-1 (sTREM-1)
is released in the peripheral blood during infectious aggres-
sion in mouse. We also confirm monocytes as a major source
of sTREM and show that a synthetic peptide mimicking a
part of the extracellular domain of TREM-1 can modulate
cytokine production by activated monocytes in vitro. We
further demonstrate that the same peptide also modulates in
vivo the proinflammatory cascade triggered by infection,
thus inhibiting hyper-responsiveness and death in an animal
model of sepsis.
 
Materials and Methods
 
Preparation of Monocytes from Peripheral Blood.
 
10 ml of pe-
ripheral blood samples were collected on EDTA-K from five
healthy volunteer donors originating from laboratory staff. After
dilution in RPMI (Life Technologies) vol/vol, blood was centri-
fuged for 30 min at room temperature over a Ficoll gradient
(Amersham Biosciences) to isolate PBMCs. The cells recovered
above the gradient were washed and counted. To deplete the sus-
pensions of lymphocytes, cells were then plated in 24-well flat-
bottom tissue culture plates (Corning) at a concentration of 5 
 
 
 
10
 
6
 
/ml and allowed to adhere during 2 h at 37
 
 
 
C. The resulting
lymphocyte suspension was discarded, and the adhering mono-
cytic cells were maintained in a 5% CO
 
2
 
 incubator at 37
 
 
 
C in
complete medium (RPMI 1640, 0.1 mM sodium pyruvate, 2
mM penicillin, 50 
 
 
 
g/ml streptomycin; Life Technologies) sup-
plemented with 10% FCS (Invitrogen).
 
TREM-1 Peptide.
 
Based on the TREM-1 sequence in Gen-
Bank/EMBL/DDBJ (under accession nos. AF287008 and AF241219),
a domain highly conserved in mouse and man was found in the
extracellular portion of the protein. The corresponding con-
served domain (LQVTDSGLYRCVIYHPP) was chemically syn-
thesized as a COOH terminally amidated peptide (Pepscan Sys-
tems). The correct peptide was obtained in 
 
 
 
99% yield and with
measured mass of 1,961 D versus a calculated mass of 1,962 D
and was homogeneous after preparative purification, as confirmed
by mass spectrometry and analytic reversed phase-high perfor-
mance liquid chromatography. This peptide was called LP17. A
peptide containing the same amino acids as LP17 but in a differ-
ent sequence order (TDSRCVIGLYHPPLQVY) was similarly
synthesized and served as control peptide.
 
In Vitro Stimulation of Monocytes.
 
For activation, monocytes
were cultured in the presence of 
 
Escherichia coli
 
 LPS (O111:B4, 1
 
 
 
g/ml; Sigma-Aldrich). Cell viability was assessed by trypan blue
exclusion and by measuring lactate dehydrogenase release. In some
experiments, this stimulus was given in combination with TNF-
 
 
 
(5–100 ng/ml; R&D Systems), IL-1
 
 
 
 (5–100 ng/ml; R&D Sys-
tems), rIFN-
 
 
 
 (up to 100 U/ml; R&D Systems), rIL-10 (500 U/ml;
R&D Systems), or up to 100 ng/ml of LP17 or control peptide.
To activate monocytes through TREM-1, an anti–TREM-1
agonist monoclonal antibody (R&D Systems) was added as fol-
lows. Flat-bottom plates were precoated with 10 
 
 
 
g/ml anti–
TREM-1 per well. After thorough washing in PBS, the mono-
cyte suspensions were added at a similar concentration as above.
Some experiments were performed in the presence of protease
inhibitors (PMSF and Protease Cocktail Inhibitor; Invitrogen).
Cell-free supernatants were assayed for the production of TNF-
 
 
 
and IL-1
 
 
 
 by ELISA according to the recommendations of the
manufacturer (BD Biosciences). To address the effect of LP17 on
NF-
 
 
 
B activity in monocytes, an ELISA-based assay was per-
formed (BD Mercury Transfactor kit; BD Biosciences). Mono-
cytes were cultured for 24 h in the presence of 
 
E. coli
 
 LPS (O111:
B4, 1 
 
 
 
g/ml), and/or an agonist anti–TREM-1 monoclonal an-
tibody (10 
 
 
 
g/ml), and/or LP17 (100 ng/ml). Whole cell ex-
tracts were then prepared, and levels of NF-
 
 
 
B p50 and p65 were
determined according to the recommendations of the manufac-
turer. All experiments were performed in triplicate, and data are
expressed as means (SEM).
 
Identification and Quantitation of sTREM-1 Release.
 
Primary
monocytes suspensions were cultured as described above. The
cells were treated with 
 
E. coli
 
 LPS (O111:B4, 1 
 
 
 
g/ml) for 24 h
at 37
 
 
 
C. Cell-conditioned medium was submitted to Western
blotting using an anti–TREM-1 monoclonal antibody (R&D
Systems) in order to confirm the presence of 27 kD material rec-
ognized by anti–TREM-1. Soluble TREM-1 levels were mea-
sured by assessing the optical intensity of bands on immunodots
by means of a reflectance scanner and the Quantity One Quanti-
tation Software (Bio-Rad Laboratories, Inc.) as reported else-
where (18). Soluble TREM-1 concentration from each sample
was determined by comparing the optical densities of the sam-
ples with reference to standard curves generated with purified
TREM-1. All measurements were performed in triplicate. The
sensitivity of this technique allows the detection of sTREM-1
levels as low as 5 pg/ml.
 
TREM-1 RT-PCR.
 
Total mRNA was extracted from pri-
mary monocytes cultured in the presence of LPS using a TRIzol
reagent (Invitrogen) and reverse transcribed using Superscript RT
II (Invitrogen) to generate cDNA. RT-PCR conditions then
used for all reactions were 94
 
 
 
C, 30 s/65
 
 
 
C, 30 s/68
 
 
 
C, and 1
min for 30 cycles. Amplification was performed with 2.5 mM
MgCl
 
2
 
, 0.2 mM dNTP, 2.0 U 
 
Taq
 
 polymerase, and 20 pM 5
 
 
 
and 3
 
 
 
 oligonucleotide primers (Proligos). The sequences of the
5
 
 
 
 and 3
 
 
 
 primer pairs used were the following: TTGTCTCA-
GAACTCCGAGCTGC and GAGACATCGGCAGTTGACT-
TGG for TREM-1 (17); GGACGGAGAGATGCCCAAGACC
and ACCAGCCAGGAGAATGACAATG for TREM-1 splice
variant (TREM-1sv) (19); and GGACGACATGGAGAAGAT-
CTGG and ATAGTAATGTCACGCACGATTTCC for 
 
 
 
-actin
used as housekeeping amplicon. PCR products were run on aga-
rose gels and visualized by ethidium bromide staining.
 
LPS-induced Endotoxinemia in Mice.
 
After approval by the lo-
cal ethical committee, male Balb/c mice (20–23 g) were randomly
grouped and treated with 
 
E. coli
 
 LPS i.p. in combination with
LP17 (in 500 
 
 
 
l normal saline) or control vector before or after
LPS challenge. In some experiments, 5 
 
 
 
g of an anti–TREM-1
monoclonal antibody was administered i.p. 1 h after LPS injec-
tion. The viability of mice was examined every hour, or animals
were killed at regular intervals. Serum samples were collected by
cardiac puncture and assayed for TNF-
 
 
 
 and IL-1
 
 
 
 by ELISA
(BD Biosciences) and for sTREM-1 levels by immunodot. 
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Cecal Ligation and Puncture Polymicrobial Sepsis Model.
 
Male
Balb/c mice (7–9 wk, 20–23 g) were anesthetized by i.p. adminis-
tration of ketamine and xylazine in 0.2 ml sterile pyrogen-free sa-
line. The cecum was exposed through a 1.0-cm abdominal mid-
line incision and subjected to a ligation of the distal half followed
by two punctures with a G21 needle. A small amount of stool was
expelled from the punctures to ensure patency. The cecum was
replaced into the peritoneal cavity and the abdominal incision
closed in two layers. After surgery, all mice were injected s.c. with
0.5 ml of physiologic saline solution for fluid resuscitation and s.c.
every 12 h with 1.25 mg (i.e., 50 
 
 
 
g/g) of imipenem. The ani-
mals were randomly grouped and treated with normal saline (
 
n
 
 
 
 
 
14), the control peptide (
 
n
 
 
 
  
 
14, 100 
 
 
 
g) or LP17 (100 
 
 
 
g) in a
single injection at H0 (
 
n
 
 
 
  
 
18), H
 
 
 
4 (
 
n
 
   
 
18), or H
 
 
 
24 (
 
n
 
 
 
 
 
18). The last group of mice (
 
n
 
 
 
  
 
18) was treated with repeated in-
jections of LP17 (100 
 
 
 
g) at H
 
 
 
4, H
 
 
 
8, and H
 
 
 
24. All treat-
ments were diluted into 500 
 
 
 
l of normal saline and administered
i.p. We next sought to determine the effect of various doses of
LP17. For this purpose, mice (
 
n
 
 
 
  
 
15 per group) were treated
with a single injection of normal saline or 10, 20, 50, 100,
 
 
 
or 200
of LP17 at H0 after the cecal ligation and puncture (CLP) and
monitored for survival. Five additional animals per group were
killed under anesthesia at 24 h after CLP for the determination of
bacterial count and cytokines levels. Peritoneal lavage fluid was
obtained using 2 mL RPMI 1640 (Life Technologies), and blood
was collected by cardiac puncture. Concentrations of TNF-
 
 
 
 and
IL-1
 
 
 
 in the serum were determined by ELISA (BD Biosciences).
For the assessment of bacterial counts, blood and peritoneal lavage
fluid were plated in serial log dilutions on tryptic soy supple-
mented with 5% sheep blood agar plates. After plating, tryptic soy
agar plates were incubated at 37
 
 
 
C aerobically for 24 h and anaer-
obically for 48 h. Results are expressed as CFU per ml of blood
and CFU per mouse for the peritoneal lavage.
 
Statistical Analyses.
 
Serum sTREM-1 and cytokines levels
were expressed as mean (
 
  
 
SD). The protection against LPS le-
thality by LP17 was assessed by comparison of survival curves us-
ing the Log-Rank test. All statistical analyses were completed
with Statview software (Abacus Concepts) and a two-tailed P 
 
 
 
0.05 was considered significant.
 
Results
 
A Soluble Form of TREM-1 Is Released from Cultured Hu-
man Monocytes after Stimulation with E. coli LPS.
 
To identify
the potential release of sTREM-1 in vitro, we stimulated
human monocytes with LPS and analyzed the conditioned
culture medium by SDS–PAGE. LPS stimulation induced
the appearance of a 27-kD protein in a time-dependent
manner (Fig. 1 A). Western blotting analysis revealed that
this protein was specifically recognized by a monoclonal an-
tibody directed against the extracellular domain of TREM-1
(Fig. 1 A). Cell viability was unaffected at LPS concentra-
tions that induced the presence of sTREM-1 in conditioned
medium, indicating that TREM-1 release was not due to
cell death. Similarly, treatment of monocytes with pro-
tease inhibitors did not affect TREM-1 release (Fig. 1 A).
TREM-1 mRNA levels were increased upon LPS treat-
ment (Fig. 1 B), whereas TREM-1sv mRNA levels re-
mained undetectable. This suggests that TREM-1 release is
likely to be linked to an increased transcription of the gene
and unrelated to TREM-1sv expression.
Stimulation of monocytes for 16 h with TNF-
 
 
 
 (5–100
ng/ml) or IL-1
 
 
 
 (5–100 ng/ml) induced very small
TREM-1 release in a cytokine dose-dependent manner.
Stimulation with IFN-
 
 
 
 did not induce TREM-1 release,
even at concentrations of up to 100 U/ml.
 
LPS-associated Release of Proinflammatory Cytokines Is At-
tenuated by LP17.
 
Significant TNF-
 
 
 
 and IL-1
 
 
 
 produc-
tion was observed in the supernatant of monocytes cul-
tured with LPS. TNF-
 
 
 
 and IL-1
 
 
 
 production was even
higher for cells cultured with both TREM-1 mAb and
LPS compared with those cultured with mAb or LPS alone
(Fig. 2 A).
The inducible release of proinflammatory cytokines was
significantly lower after LPS stimulation when the medium
was supplemented with LP17 or IL-10. LP17 reduced, in a
concentration-dependent manner, the TNF-
 
 
 
 and IL-1
 
 
 
production from cells cultured with LPS or with LPS and
mAb and simultaneously increased the release of sTREM-1
from cells cultured with LPS. The control peptide dis-
played no action on cytokines or sTREM-1 release (not
depicted). In striking contrast, IL-10 totally inhibited the
release of both TREM-1 and inflammatory cytokines (Fig.
2 A). Both LPS and TREM-1 mAb induced a strong acti-
vation of monocytic NF-
 
 
 
B p50 and p65, and combined
administration of LPS and TREM-1 mAb lead to a syner-
gistic effect. LP17 inhibited the NF-
 
 
 
B activation induced
Figure 1. (A) Release of sTREM-1 from cultured monocytes after
stimulation with LPS with and without proteases inhibitor. LPS stimula-
tion induced the appearance of a 27-kD protein that was specifically rec-
ognized by an anti–TREM-1 mAb (inset). sTREM-1 levels in the condi-
tioned culture medium were measured by reflectance of immunodots.
Data are shown as mean   SD (n   3). (B) Expression of TREM-1
mRNA in monocytes. Cultured monocytes were stimulated with LPS
(1  g/ml) for 0, 1, and 16 h as indicated. LPS induced TREM-1 mRNA
production within 1 h.TREM-1 Modulation in Murine Sepsis 1422
by the engagement of TREM-1 but did not alter the effect
of LPS (Fig. 2 B).
Serum sTREM-1 Levels of LPS-treated Mice Are Increased.
To determine whether sTREM-1 was released systemically
during endotoxemia in mice, we measured serum sTREM-1
levels after LPS administration. Serum sTREM-1 was readily
detectable 1 h after administration of an LD50 dose of LPS
and was maintained at peak plateau levels from 4 to 6 h af-
ter LPS treatment (Fig. 3).
LP17 Protects Endotoxemic Mice from Lethality. Mice
treated by a single dose of LP17 60 min before a lethal dose
(LD100) of LPS were prevented from death in a dose-
dependent manner (Fig. 4 A). To investigate whether
LP17 treatment could be delayed until after the administra-
tion of LPS, we injected LP17 beginning 4 or 6 h after LPS
injection. This delayed treatment up to 4 h conferred sig-
nificant protection against an LD100 dose of LPS (Fig. 4 B).
No late death occurred over 1 wk, indicating that LP17 did
not merely delay the onset of LPS lethality but provided
lasting protection. Control mice all developed lethargy, pi-
loerection, and diarrhea before death. By contrast, LP17-
Figure 2. (A) Release of cytokines and sTREM-1 from cultured
monocytes. For cell activation, primary monocytes were cultured in 24-
well flat-bottom tissue culture plates in the presence of LPS (1  g/ml). In
some experiments, this stimulus was provided in combination with LP17
(10–100 ng/ml), control peptide (10–100 ng/ml), or rIL-10 (500 U/ml).
To activate monocytes through TREM-1, an agonist anti–TREM-1
mAb (10  g/ml) was added as indicated. Cell-free supernatants were ana-
lyzed for production of TNF- , IL-1 , and sTREM-1 by ELISA or im-
munodot. All experiments were performed in triplicate and data are ex-
pressed as means (SEM). (a) Media; (b) LP17 10 ng/ml; (c) anti–TREM-1;
(d) LPS; (e) LPS   anti–TREM-1; (f) LPS   LP17 10 ng/ml; (g) LPS  
LP17 50 ng/ml; (h) LPS   LP17 100 ng/ml; (i) LPS   IL10. (B) Effect of
LP17 on NF- B activation. Monocytes were cultured for 24 h in the
presence of E. coli LPS (O111:B4; 1  g/ml), anti–TREM-1 mAb (10
 g/ml), and/or LP17 (100 ng/ml) as indicated, and the levels of NF- B
p50 and p65 were determined using an ELISA-based assay. Experiments
were performed in triplicate, and data are expressed as means of optical
densities (SEM).
Figure 3. Accumulation of
sTREM-1 in serum of LPS-
treated mice. Male Balb/c mice
(20–23 g) were treated with LPS
(LD50, intraperitoneally). Serum
was assayed for sTREM-1 by
immunodot. Serum sTREM-1
was readily detectable 1 h after
LPS administration and was
maintained at a plateau level
from 4 to 6 h.
Figure 4. Endotoxinic shock in mice. (A) LP17 pretreatment protects
against LPS lethality in mice. Male Balb/c mice (20–23 g) were randomly
grouped (10 mice per group) and treated with an LD100 of LPS. LP17
(50 or 100  g) or control vector was administered 60 min before LPS.
(B) Delayed administration of LP17 protects LPS lethality in mice. Male
Balb/c mice (20–23 g) were randomly grouped (8 mice per group) and
treated with an LD100 of LPS. LP17 (75  g) or control vector was admin-
istered 4 or 6 h after LPS as indicated. (C) Administration of agonist
TREM-1 mAb is lethal to mice. Male Balb/c mice (20–23 g) were ran-
domly grouped (eight mice per group) and treated with a combination of
an LD50 of LPS   control vector, LD50 of LPS   anti-TREM-1 mAb
(5  g), or LD100 of LPS   control vector as indicated. Control vector and
anti–TREM-1 mAb were administered 1 h after LPS injection.Gibot et al. 1423
treated mice remained well groomed and active, had no di-
arrhea, and were lively. To clarify the mechanism by which
LP17 protected mice from LPS lethality, we determined the
serum levels of TNF- , IL-1 , and sTREM-1 of endotox-
emic mice at 2 and 4 h. Compared with controls, pretreat-
ment by 100  g of LP17 reduced cytokines levels by 30%
and increased sTREM-1 levels by twofold (Table I).
Engagement of TREM-1 Is Lethal to Mice. To further
highlight the role of TREM-1 engagement in LPS-medi-
ated mortality, mice were treated with agonist anti–TREM-1
mAb in combination with the administration of an LD50
dose of LPS. This induced a significant increase in mortal-
ity rate from 50 to 100% (Fig. 4 C).
LP17 Protects Mice from CLP-induced Lethality. To in-
vestigate the role of LP17 in a more relevant model of sep-
tic shock, we performed CLP experiments (Fig. 5 A). The
control groups comprised mice injected with normal saline
or with the control peptide. In this model of polymicrobial
sepsis, LP17 still conferred a significant protection against
lethality even when administered as late as 24 h after the
onset of sepsis. Interestingly, repeated injections of LP17
had the more favorable effect on survival (P < 0.01). There
was a dose–response effect of LP17 on survival (Fig. 5 b)
and cytokines production (Table II). LP17 had no effect on
bacterial clearance (Fig. 6).
Discussion
Sepsis exemplifies a complex clinical syndrome that re-
sults from a harmful or damaging host response to severe
infection. Sepsis develops when the initial, appropriate host
response to systemic infection becomes amplified and then
dysregulated (4, 5). Neutrophils and monocyte/macro-
phages exposed to LPS, for instance, are activated and release
such proinflammatory cytokines as TNF-  and IL-1 . Ex-
cessive production of these cytokines is widely believed to
contribute to the multiorgan failure that is seen in septic
patients (20–23).
TREM-1 is a recently identified molecule involved in
monocytic activation and inflammatory response (12, 14).
It belongs to a family related to NK cell receptors that
activate downstream signaling events. The expression of
TREM-1 on PMNs and monocytes/macrophages has been
shown to be inducible by LPS (16, 17).
Table I. Serum Concentrations of TNF- , IL-1 , and sTREM-1 in Endotoxemic Mice
TNF-  IL-1  sTREM-1 
ng/mL ng/mL ng/mL
H2 H4 H2 H4 H2 H4
Control 3.3   1.0 0.4   0.1 0.3   0.1 1.5   0.2 249   48 139   8
LP17 (100  g) 2.4   0.5 0.1   0.1 0.2   0.1 0.9   0.2 475   37 243   28
Figure 5. CLP polymicrobial sepsis model. (A) LP17 partially protects
mice from CLP-induced lethality. Male Balb/c mice (20–23 g) were ran-
domly grouped and treated with normal saline (n   14) or the control
peptide (n   14; 100  g) or with LP17 (100  g) in a single infection at
H0 (n   18), H 4 (n   18), or H 24 (n   18). The last group of mice
(n   18) was treated with repeated injections of LP17 (100  g) at H 4,
H 8, and H 24. (B) Dose effect of LP17 on survival. Mice (n   15 per
group) were treated with a single injection of normal saline or 10, 20, 50,
100, or 200  g of LP17 at H0 after the CLP and monitored for survival.
Table II. Serum Concentrations of TNF- , IL-1 , and 
sTREM-1 at 24 h after CLP
TNF- 
pg/mL
IL-1 
pg/mL
sTREM-1
ng/mL
Control peptide 105   12 841   204 35   5
Control saline 118   8 792   198 35   5
LP17 10  g 110   11 356   62 43   8
LP17 20  g 89   10 324   58 58   8
LP17 50  g 24   6 57   11 93   10
LP17 100  g 20   3 31   3 118   12
LP17 200  g 21   7 37   8 158   13TREM-1 Modulation in Murine Sepsis 1424
Here, we report that a soluble form of TREM-1 was re-
leased from cultured human monocytes after stimulation
with E. coli LPS. Such a soluble form was also detectable
in the serum of endotoxemic mice as early as 1 h after
LPS challenge. This is consistent with the implication of
TREM-1 in the very early phases of the innate immune re-
sponse to infection (14, 15, 24). The mechanism by which
sTREM-1 is released is not clearly elucidated but seems to
be related to an increased transcription of the TREM-1
gene. Nevertheless, although incubation with a protease in-
hibitor cocktail does not alter the sTREM-1 release, cleav-
age of the surface TREM-1 from the membrane cannot be
totally excluded. Interestingly, stimulation of human mono-
cytes with such proinflammatory cytokines as TNF- , IL-
1 , or IFN-  induced very small sTREM-1 release unless
LPS was added as a costimulus. The expression of an alter-
native mRNA TREM-1sv has been detected in monocytes
that might translate into a soluble receptor (18) upon stimu-
lation with cell wall fraction of Mycobacterium bovis BCG but
not LPS (25). This was confirmed in this study as (a) LPS
did not increase the level of mRNA TREM-1sv in mono-
cytes and (b) only a 27-kD protein was released by mono-
cytes upon LPS stimulation and not the 17.5-kD variant.
Although its natural ligand has not been identified (13,
14), engagement of TREM-1 on monocytes with an agonist
monoclonal antibody resulted in a further enhancement of
proinflammatory cytokines production, whereas LP17 induced
a decrease of these syntheses in a concentration-dependent
manner, and IL-10 completely suppressed it.
Inflammatory cytokines, and especially TNF- , are con-
sidered to be deleterious, yet they also possess beneficial ef-
fects in sepsis (5) as shown by the fatal issue of peritonitis in
animals with impaired TNF-  responses (9–11). More-
over, in clinical trials the inhibition of TNF-  increased
mortality (8). Finally, the role of TNF-  in the clearance of
infection has been highlighted by the finding that sepsis is a
frequent complication in rheumatoid arthritis patients treated
with TNF-  antagonists (26).
The mechanism by which LP17 modulates cytokine
production is not yet clear. LP17 comprises the comple-
mentary determining region-3 and the “F”   strand of the
extracellular domain of TREM-1. The latter contains a ty-
rosine residue mediating dimerization. Radaev et al. postu-
lated that TREM-1 captures its ligand with its comple-
mentary determining region-equivalent loop regions (27).
Thus, LP17 could impair the TREM-1 dimerization and/or
compete with the natural ligand of TREM-1. Moreover,
the increase of sTREM-1 release from monocytes medi-
ated by LP17 could prevent the engagement of membrane
TREM-1, sTREM-1 acting as a decoy receptor, as in the
TNF-  system (28, 29).
Activation of the transcription factor NF- B is a critical
step in monocyte inflammatory cytokine production after
exposure to bacterial stimuli such as LPS (30, 31). Among
the various NF- B/Rel dimers, the p65/p50 heterodimer
is the prototypical form of LPS-inducible NF- B in mono-
cytes (32). LP17 abolishes the p65/p50 NF- B overactiva-
tion induced by the engagement of TREM-1. This might
at least partially explain the effects of LP17 on cytokine
production and the protection from lethality shown here to
occur when the peptide was injected 1 h before LPS-
induced septic shock, or even up to 4 h after.
Endotoxemia is simple to achieve experimentally but
imperfectly suited to reproduce human sepsis, whereas
polymicrobial sepsis induced by CLP is a more complex
but better model, including the use of fluid resuscitation
and antibiotics. Thus, the latter was also used in this study
and confirmed the dose-dependent protection provided by
LP17, even when administered as late as 24 h after the on-
set of sepsis. However, the favorable effect of LP17 was un-
related to an enhanced bacterial clearance.
One difficulty in the use of immunomodulatory thera-
pies is that it is not possible to predict the development of
sepsis, and thus patients receiving those treatments fre-
quently already have well-established sepsis (6). Since LP17
appeared to be effective even when injected after the out-
break of sepsis, it could thus constitute a realistic treatment
(24, 33).
By contrast, engagement of TREM-1 by an agonist
anti–TREM-1 monoclonal antibody mediated a dramatic
increase of mortality rate in LPS-challenged mice: this fur-
ther underscores the detrimental effect of TREM-1 en-
gagement during septic shock.
Experimental septic shock reproduces human sepsis only
in part. Indeed, our group recently showed that significant
levels of sTREM-1 were released in the serum of critically
ill patients with sepsis patients (34), the highest levels being
observed in patients who survived. This is consistent with
our experimental findings indicating that the more impor-
tant sTREM-1 release, the more favorable is the outcome,
and thus sustains, at least theoretically, the potential value
of soluble TREM peptides as postonset sepsis therapy.
TREM-1 appears to be a crucial player in the immediate
immune response triggered by infection. In the early phase
of infection, neutrophils and monocytes initiate the inflam-
matory response owing to the engagement of pattern rec-
ognition receptors by microbial products (3, 4). At the
same time, bacterial products induce the up-regulation and
Figure 6. LP17 has no effect on bacterial counts during CLP. Mice (5
per group) were killed under anesthesia at 24 h after CLP. Bacterial
counts in peritoneal lavage fluid and blood were determined and results
are expressed as CFU per ml of blood and CFU per mouse for the perito-
neal lavage.Gibot et al. 1425
the release of sTREM-1. Upon recognition of an un-
known ligand, TREM-1 activates signaling pathways which
amplify these inflammatory responses, notably in mono-
cytes/macrophages. The modulation of TREM-1 signaling
reduces, although without complete inhibition, cytokine
production and protects septic animals from hyper-respon-
siveness and death. Modulation of TREM-1 engagement
with such a peptide as LP17 might be a suitable therapeutic
tool for the treatment of sepsis, particularly because it seems
to be active even after the onset of sepsis after infectious
aggression.
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